clinical trial · NCT02558231
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Actelion·phase3·completed·n = 247
Pulmonary Arterial HypertensionMacitentanTadalafilSelexipag
brief summary
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
started
May 1, 2016
primary completion
Aug 29, 2019
completion
Apr 20, 2020
last updated
Mar 30, 2025
official title
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol